This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national tr...ends in communicable and non-communicable disease burden and control in the WHO African region. It tracks progress made with respect to disease burden reduction, elimination and eradication. It also highlights major emerging threats, opportunities and priorities in the fight against commu- nicable and non-communicable diseases in the region. It covers the period 2000-2022, but for some indicators, information is available only up to 2021.
The report shows the number of reported cases for malaria and vaccine preventable diseases (meningitis, measles, yellow fever, pertussis, diphtheria, tetanus, and polio); disease incidence due to HIV, tuberculosis and four major noncommunicable diseases (cardiovas- cular diseases, cancers, diabetes and chronic respira- tory diseases).
more
This report summarizes the findings of the Health Financing Progress Matrix assessment for Zambia. Recognizing the remarkable progress towards UHC made by the country over the past twenty years, the report... also highlights weaknesses in the current health financing system and, extending from this, those priority issues to be addressed in order to further accelerate Zambia’s progress towards universal health coverage (UHC).
more
This report summarizes the findings of the Health Financing Progress Matrix assessment for Zambia. Recognizing the remarkable progress towards UHC made by the country over the past twenty years, the report... also highlights weaknesses in the current health financing system and, extending from this, those priority issues to be addressed in order to further accelerate Zambia’s progress towards universal health coverage (UHC).
more
This report explores the extent to which evidence, policy, normative guidance and commitments on HIV and gender-based violence, and their interlinkages, is being translated into action on the ground in fragile settings. These issues are explored thr...ough the lens of training of peace support operations deploying African troops across Africa and beyond.
more
This report on global leishmaniasis surveillance follows those published in 2016–2023.2–6 Six indicators of leishmaniasis are publicly available from the Global Health Observatory (GHO).7 In addition to the GHO, country profiles with up to 30 in...dicators are published, with detailed data received from 45 Member States.
more
WHO TEchnical REport SEries No. 849
The Global Action Report on Preterm Birth. Presentation
This interagency report provides recommendations for assuring quality of medicines during key activities of country-level procurement agencies, namely prequalification of pharmaceutical products and manufacturers; purchase of pharmaceutical products...; storage of pharmaceutical products; and distribution of pharmaceutical products.
more
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of... key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
more
Findings from this report reveal that, rates of early marriage are high, a significant percentage of children contribute to the household’s income or are its main source of income, and restrictions on the mobility of women and girls constrain thei...r participation in social and economic activities and their access to basic services. As the overwhelming majority of refugees do not have paid employment and rely mainly on aid and dwindling family resources, the more the situation of displacement is prolonged the greater the likelihood of higher rates of child labour for boys and early marriage for girls.
more
Morbidity and Mortality Weekly Report Suppl. Vol.63/3
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report...pan> includes information on seven experimental medicines intended for the treatment of people infected with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Morbidity and Mortality Weekly Report (MMWR):
Morbidity and Mortality Weekly Report (MMWR) January 16, 2015 / 64(01);20-27
Second interim report to the SMAC program, DFID Freetown
This report provides further output from an anthropological study of 25 villages affected by Ebola Virus Disease in eastern and central Sier...ra Leone, undertaken as part of the DFID-funded social mobilization initiative for Ebola prevention in Sierra Leone. Eight focus group transcripts for 3 villages in Kenema District are presented, covering local responses to health issues, and Ebola in particular. Supporting material from a matching questionnaire-based study of health behavior and perceived causes of Ebola is also provided. Of particular relevance are two summary tables aggregating the questions villagers asked survey teams about Ebola and quarantine-related issues in villages where the epidemic has in effect ceased to be active
more
Fifth interim report to the SMAC program, DFID Freetown
Key strategies for preventing further infection are isolation of the patient in an Ebola care facility, “safe burial”, and quarantine of those exposed to Ebola cases. Equally important is ...social recognition that isolation, safe burial and quarantine are necessary to break the transmission chain. Thus it is important to ask how, and how quickly, communities learn about the risks of infection and the necessity of steps to reduce and eliminate these risks
more
The third report in the series Resources for Results published by the UN Office of the Special Envoy on Ebola provides an overview of resources announced and disbursed to countries and agencies as of 31 January 2015. This ...ighlight medbox">report is a next step towards more transparency allowing all, especially the governments in the affected countries, to effectively manage and better utilize the available resources
more
Morbidity and Mortality Weekly Report (MMWR) Early Release Vol. 64 ; 1 May 2015